Moens Lotte N, Falk-Sörqvist Elin, Asplund A Charlotta, Bernatowska Ewa, Smith C I Edvard, Nilsson Mats
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Clinical Research Center, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
PLoS One. 2014 Dec 11;9(12):e114901. doi: 10.1371/journal.pone.0114901. eCollection 2014.
Primary Immunodeficiencies (PID) are genetically inherited disorders characterized by defects of the immune system, leading to increased susceptibility to infection. Due to the variety of clinical symptoms and the complexity of current diagnostic procedures, accurate diagnosis of PID is often difficult in daily clinical practice. Thanks to the advent of "next generation" sequencing technologies and target enrichment methods, the development of multiplex diagnostic assays is now possible. In this study, we applied a selector-based target enrichment assay to detect disease-causing mutations in 179 known PID genes. The usefulness of this assay for molecular diagnosis of PID was investigated by sequencing DNA from 33 patients, 18 of which had at least one known causal mutation at the onset of the experiment. We were able to identify the disease causing mutations in 60% of the investigated patients, indicating that the majority of PID cases could be resolved using a targeted sequencing approach. Causal mutations identified in the unknown patient samples were located in STAT3, IGLL1, RNF168 and PGM3. Based on our results, we propose a stepwise approach for PID diagnostics, involving targeted resequencing, followed by whole transcriptome and/or whole genome sequencing if causative variants are not found in the targeted exons.
原发性免疫缺陷病(PID)是一类遗传性疾病,其特征为免疫系统存在缺陷,导致机体更容易受到感染。由于临床症状多样且当前诊断程序复杂,在日常临床实践中,准确诊断PID往往具有挑战性。得益于“下一代”测序技术和靶向富集方法的出现,如今开发多重诊断检测成为可能。在本研究中,我们应用了一种基于选择器的靶向富集检测方法,以检测179个已知PID基因中的致病突变。通过对33例患者的DNA进行测序,研究了该检测方法对PID分子诊断的实用性,其中18例患者在实验开始时至少有一个已知的致病突变。我们能够在60%的受调查患者中鉴定出致病突变,这表明大多数PID病例可以通过靶向测序方法得到解决。在未知患者样本中鉴定出的致病突变位于STAT3、IGLL1、RNF168和PGM3基因中。基于我们的研究结果,我们提出了一种PID诊断的逐步方法,包括靶向重测序,如果在靶向外显子中未发现致病变异,则随后进行全转录组和/或全基因组测序。